Can a magnolia supplement calm psoriasis inflammation?

NCT ID NCT07471048

Recruiting now Disease control Sponsor: Sirt3 LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a daily magnolia bark supplement (Viv) can reduce immune-related blood markers in adults with psoriasis. One hundred participants will take either the supplement or a placebo for three months. Researchers will measure changes in inflammatory proteins and immune cells from blood samples collected at home.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Magnolia officinalis bark extract (200 mg oral supplement)
What this could lead to: If it works, this could point toward a natural supplement that helps control psoriasis by lowering inflammation.
What could go wrong: This is an early-stage trial with only 100 people, testing blood markers—not symptoms. The supplement may have no real effect, and results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Decentralized Study Coordinating Center
RECRUITING

Englewood, New Jersey, 07631, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.